From: Childhood Acute Myeloid Leukemia Treatment (PDQ®)
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Lineage | Criterion |
---|---|
B lineage | |
CD19 strongb, OR | 1 or more also strongly expressed: CD10, CD22, or CD79ad |
CD19 weakc | 2 or more also strongly expressed: CD10, CD22, or CD79ad |
T lineage | |
CD3 (cytoplasmic or surface)e | Intensity in part exceeds 50% of mature T-cells level by flow cytometry or immunocytochemistry positive with non-zeta chain reagent |
Myeloid lineage | |
Myeloperoxidase, OR | Intensity in part exceeds 50% of mature neutrophil level |
Monocytic differentiation | 2 or more expressed: Nonspecific esterase, CD11c, CD14, CD64, or lysozyme |
aCredit: Khoury, J.D., Solary, E., Abla, O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36, 1703–1719 (2022). https://doi
bCD19 intensity in part exceeds 50% of normal B cell progenitor by flow cytometry.
cCD19 intensity does not exceed 50% of normal B cell progenitor by flow cytometry.
dProvided T lineage not under consideration, otherwise cannot use CD79a.
eUsing anti-CD3 epsilon chain antibody.
From: Childhood Acute Myeloid Leukemia Treatment (PDQ®)
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.